The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

StocksMedium•8 April 2026•

1 min read

Silo Pharma Shares Surge on European Patent Office Allowance

Key Facts

1Silo Pharma received a Rule 71(3) communication from the European Patent Office indicating its intent to grant a patent.

2The company holds an exclusive license for the patent application from Columbia University.

3The company's shares rallied immediately following the announcement of this intellectual property development.

Silo Pharma (SILO) shares experienced a significant rally following a positive update regarding its intellectual property portfolio in Europe. The company received a Rule 71(3) communication from the European Patent Office (EPO), indicating an intent to grant a key patent. This patent application is exclusively licensed to Silo Pharma from Columbia University, significantly strengthening the firm's competitive position. Securing patent protection in major international markets is considered a vital milestone for biotechnology companies to safeguard their R&D investments. The move ensures future commercial exclusivity for the underlying technology within the European jurisdiction. Market participants responded bullishly to the news, driving the stock price higher immediately after the announcement.

Create Free Account